12 Week Study for Patients with Moderate to Severe Acne
Aim: This new clinical trial is studying how well a new topical foam treatment works versus a placebo. Study treatment is assigned randomly and is administered daily for 12 weeks. Criteria for participation in the study is as follows:
- Patients must be 9 years and older
- Patient must have have visible signs of moderate to severe active acne on their face that consist of red irritated pimples along with whiteheads and blackheads
- Patients must have the ability to make a maximum of 7 office visits and 3 blood draws
Eligible patients can receive up to $350.00 as compensation along with free study-related medical evaluations and study medication. There is no cost to enroll in the trial and insurance is not required. Convenient appointment hours are available from 6:00 am to 1:00 pm in order to accommodate busy school and work schedules. In addition to possible acne relief, participation in this study helps provide important information about the safety and effectiveness of this new topical acne treatment.
Diagnosis: Moderate to Severe Acne
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH17-275
Sponsor: Foamix Pharmaceuticals
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email firstname.lastname@example.org (also accessible by clicking either button above and below on this page) and including the subject line "Dermatology Acne Clinical Trial"
Open to Enrollment:Yes, as of October 2017